About 500 patients with severe obesity are expected to be enrolled in the phase 2 trial. Results from this trial will have the potential to identify future patient populations and to inform the design of future registrational studies to support label expansion.
Meanwhile, Rhythm said it expects to launch three additional phase 3 trials of setmelanotide this year.
Price: 8.62, Change: +0.06, Percent Change: +0.70
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|
|--April Unemployment Rate Fell in 13 US States, Payr...|
|Marvell Technology Likely to See Fiscal Q1 Beat, Opp...|
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Terreno Realty Acquires Newark Industrial Property f...|